Belgium· BE-AMP-SAM661004-00
Ebvallo 2.8 10*7 cells/ml - 7.3 10*7 cells/ml
A tabelecleucel product containing tabelecleucel, registered in Belgium by Pierre Fabre Médicament. The same ATC class is registered in 11 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Tabelecleucel is registered in 11 of 19 countries.
Countries holding a registration under ATC L01XL09 (tabelecleucel), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Tabelecleucel · ATC L01XL09
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Tabelecleucel
- Manufacturer
- Pierre Fabre Médicament
- Country
- Belgium (BE)
- ATC code
- L01XL09
- ATC class
- Tabelecleucel
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4731303
- be_apb7740723
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tabelecleucel in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandEbvallo, InjektionsdispersionPierre Fabre Pharma SA
- CzechiaEBVALLOPIERRE FABRE MEDICAMENT, Lavaur
- SpainEBVALLO 2,8 × 10E7 - 7,3 × 10E7 CÉLULAS /ML DISPERSION INYECTABLEPierre Fabre Medicament
- FinlandEbvalloPierre Fabre Medicament
- FranceEBVALLO 2,8 x 10 000 000 - 7,3 x 10 000 000 cellules/mL, dispersion injectablePIERRE FABRE MEDICAMENT
- IrelandEbvallo 2.8 × 10^7 – 7.3 × 10^7 cells/mL dispersion for injectionPierre Fabre Medicament
- IcelandEbvalloPierre Fabre Medicament
- NetherlandsEbvallo 5×10E7 cellen/ml, dispersie voor injectiePierre Fabre Medicament
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ebvallo
- Liechtenstein · Ebvallo
- Norway · Ebvallo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2d6dbec3-422b-4189-b6de-46141db81670 GET /v1/drugs/2d6dbec3-422b-4189-b6de-46141db81670?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dispersion for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Ebvallo 2.8 10*7 cells/ml - 7.3 10*7 cells/ml",
"name_fr": "Ebvallo 2.8 10*7 cells/ml - 7.3 10*7 cells/ml",
"name_nl": "Ebvallo 2.8 10*7 cells/ml - 7.3 10*7 cells/ml",
"amp_code": "SAM661004-00",
"strengths": [
"2.8000",
"2.8000"
],
"pack_count": 1,
"substances": [
"Tabelecleucel",
"Dimethyl Sulfoxide",
"Phosphate Buffered Saline"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Tabelecleucel",
"authorisation_numbers": [
"EU/1/22/1700/001"
]
}See everything about tabelecleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.